Droplex KRAS Mutation Test v2
Detection of the 28 defined mutations within the KRAS oncogene
Features
Colorectal Cancer (CRC) is one of the cancers with the most incidents & mortality rate around the globe. KRAS mutation is the most common driver mutation in colorectal cancer patients which accounts about 30 ~ 40 % of total cases. KRAS G12C mutation is also an important mutation for Non-small Cell Lung Cancer (NSCLC) patients, which occurs in 13 % of all NSCLC cases. The CE-IVD certified Droplex KRAS Mutation Test v2 detects 28 defined mutations within the KRAS oncogene using Digital DropletTM Technology. This companion diagnostic test helps identify CRC and NSCLC patients who are eligible for tailored treatment.
BIOTYPE is the exclusive distributor of the Droplex Test Series in Germany. Legal manufacturer of the kits is GENCURIX, Inc.
Biomarkers
Exon 2: G12C/S/R/V/D/A, G13D
Exon 3: A59T/E/G, Q61K/E/P/R/L/H
Exon 4: K117E/R/N, A146P/S/T/G/V/I
Product specifications
- Cat. No.
- CD012
- Cancer type
- Colorectal Cancer, Non-Small Cell Lung Cancer
- Regulatory status
- CE-IVD
- Compatible sample type
- DNA from FFPE tissue, cfDNA from Plasma
- Mutation variants
- 28
- Kit size/reactions
- 24 samples/kit (4 well-reactions/sample)
- Platform
- Digital DropletTM PCR
Resources
Ordering Information
Droplex KRAS Mutation Test v2
Kit size: 24 samples/kit (4 well-reactions/sample)
Cat. No.: CD012
Status: CE-IVD
Product Request
MODAPLEX
Bench-top system for molecular multi-marker testing
